Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Butaclamol”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 271 records · Page 15Linked to original sources
PubMed1976

Attenuation of intravenous amphetamine reinforcement by central dopamine blockade in rats.

Norepinephrine (NE) and dopamine (DA) receptor blockade differentially affected amphetamine self-administration. DA blockade (pimozide, 0.0625 to 0.5 mg/kg, or (+)-butaclamol, 0.0125 to 0.1 mg/kg) caused periods of increased rate of responding for amphetamine which were followed, in the case of higher doses, by response cessation. The response cessation produced by 0.5 mg/kg pimozide was not reversed by non-contingent amphetamine injections until well after the peak effect of the pimozide was over. When access to amphetamine injections was delayed until 4 h after animals received 0.5 mg/kg pimozide, rate of responding was elevated. Thus DA seems to be critically involved in mediation of the reinforcing effects of amphetamine. Alpha-NE blockade with phentolamine (2.5-10 mg/kg) produced dose-related decreases in responding; blockade with phenoxybenzamine (1.25-10 mg/kg) had no effect. Beta-NE blockade with l-propranolol (2.5-10 mg/kg) decreased responding, although probably not through a beta-blocking action. The effects of phentolamine and propranolol do not appear to result from attenuation of the reinforcing effects of amphetamine.

Animals↗
PubMed1986

Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners of 3-PPP.

In the further development of CNS dopamine autoreceptor active compounds related to 3-PPP, the transfused 7-hydroxy-1,2,3,4,4a,5,6,10b-octahydrobenzo(f)quinoline HW-165 and its enantiomers were synthesised. This paper describes the basic pharmacological properties of these latter, novel "atypical" dopaminergic agents, based on an extensive series of biochemical and behavioural experiments in rats. By and large, the pharmacological activities of HW-165 - essentially, if not exclusively, residing in its (4aS,10bS)-(-)-enantiomer - were similar to those displayed by (S)-(-)-3-PPP, indicating the simultaneous presence of central dopamine (autoreceptor) agonist and weak (postsynaptic) antagonist properties in the molecule. Thus, in non-pretreated animals HW-165 and its active species monotonically suppressed the spontaneous locomotion without causing catalepsy or other appreciable motor disabilities, and at the same time selectively reduced the dopamine synthesis, release/turnover and utilisation. Some differences in these biochemical responses to HW-165 [racemate or (-)-enantiomer] were, however, noted in the limbic vs. striatal brain areas (e.g. decrease of dopamine synthesis particularly in the limbic parts). On the other hand, while failing to reverse reserpine-induced akinesia or to elicit stereotyped behaviour, the agents markedly inhibited the dopamine synthesis in either of the dopamine-dominated cerebral regions in the reserpinised as well as in gamma-butyrolactone (GBL)-treated rats. As shown for racemic HW-165 after reserpine pretreatment, the inhibition of dopamine synthesis was completely and stereoselectively blocked by (+)-butaclamol, thereby supporting direct dopamine receptor interaction. Racemic HW-165 readily antagonised the d-amphetamine-induced locomotor hyperactivity. Apomorphine-induced hyperactivity was, however, distinctly more resistant to antagonism by HW-165 [racemate or (-)-enantiomer]. Moreover, the latter agents fully prevented the apomorphine-induced inhibition of striatal dopamine synthesis in otherwise non-pretreated rats, while only partly counteracting this effect of apomorphine in the limbic regions of such animals, and in either brain area of rats treated with gamma-butyro-lactone. The findings are interpreted within the context of the mixed dopamine agonist/antagonist properties (referred above) of HW-165 and its active (-)-species in relation to the adaptive state of central dopamine receptors and possible regional variations in feedback strength and organisation.(ABSTRACT TRUNCATED AT 400 WORDS)

4-Butyrolactone↗
PubMed1989

Dopamine D1 receptors labelled with [3H]SCH23390 in rabbit cerebral cortex and neostriatum. Equilibrium binding, kinetics and selectivity.

The binding characteristics of the novel benzazepine compound SCH23390 were studied using membrane preparations from rabbit cerebral cortex (CTX) and neostriatum (CPU; caudate putamen). The association kinetics of [3H]SCH23390 to membranes from CTX and CPU were rapid, while the dissociation kinetics were extremely slow and only around 40-60% of the binding was displaced two hours after the addition of either S(+)-butaclamol or 30 volumes of buffer. The saturation curves revealed that [3H]SCH23390 bound with high affinity in both tissues, with densities of 133 fmol/mg protein for CTX (Kd 25 degrees C = 0.31 nM) and 664 fmol/mg protein for CPU (Kd = 0.13 nM). the specificity of binding to the cortical D1 receptor was verified in competition experiments with a variety of dopaminergic agents. The rank order of potency of these compounds was consistent with the pharmacology of the dopaminergic D1 site. All competition curves were better fitted to a one-site model with Hill coefficients around one, indicating that [3H]SCH23390 was binding to a single cortical site. The stereoselectivity of the cortical [3H]SCH23390 binding site could be demonstrated by the use of enantiomer pairs of dopaminergic drugs. This study provides compelling evidence that [3H]SCH23390 binds to dopamine D1 receptors in the neostriatum and cerebral cortex of the rabbit.

Animals↗
PubMed1990

Solubilization and reconstitution of dopamine D1 receptor from bovine striatal membranes: effects of agonist and antagonist pretreatment.

The bovine striatal dopamine D1 receptor was solubilized with a combination of sodium cholate and NaCl in the presence of phospholipids, following treatment of membranes with a dopaminergic agonist (SKF-82526-J) or antagonist (SCH-23390). The solubilized receptors were subsequently reconstituted into lipid vesicles by gel-filtration. A comparison of ligand-binding properties shows that the solubilized and reconstituted receptors bound [3H]SCH-23390 to a homogeneous site in a saturable, stereospecific and reversible manner with a Kd of 0.95 and 1.1 nM and a Bmax of 918 and 885 fmol/mg protein respectively for agonist- and antagonist-pretreated preparations. These values are very similar to those obtained for membrane-bound receptors. The competition of antagonists for [3H]SCH-23390 binding exhibited a clear D1 dopaminergic order in the reconstituted preparation obtained from either agonist or antagonist-pretreated membranes, except that (+)butaclamol was about four-fold more potent than cis-flupentixol in displacing [3H]SCH-23390 binding in preparation obtained from agonist-pretreated membranes compared to antagonist-pretreated membranes. The agonist/[3H]SCH-23390 competition studies revealed the presence of a high-affinity component of agonist binding in both the reconstituted receptor preparations. The number of high-affinity agonist binding sites, however, is 40-80% higher in reconstituted preparation obtained from antagonist-treated membrane compared to that obtained from the agonist-treated membrane. In both the preparations, 100 microM guanylylimidodiphosphate (Gpp(NH)p) completely abolished the high-affinity component of agonist binding compared to partial abolition in the native membranes, indicating a close association of a G-protein with the solubilized receptors. Whether the receptor was solubilized following agonist or antagonist preincubation of the membranes, the receptor-detergent complex eluted from a steric-exclusion HPLC column with an apparent molecular size of 360,000. Preincubation of the solubilized preparations with Gpp(NH)p had virtually no effect on the elution profile suggesting a lack of guanine nucleotide-dependent dissociation of G-protein receptor complex.

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-ben↗
PubMed1989

Quantitative autoradiographic distribution and pharmacological characterization of (3H)buspirone binding to sections from rat, bovine and marmoset brain.

(3H)Buspirone binds with high affinity (KD = 11 nM) to sections from rat striatum. Spiroperidol, chlorpromazine, (+)-butaclamol and apomorphine are the most potent inhibitors of (3H)buspirone binding. Ketanserin, SCH 23390, serotonin and phentolamine are clearly less active. The regional distribution of (3H)buspirone binding in rat and marmoset brain is characterized by high silver grain densities in the olfactory tubercle, nucleus accumbens and striatum. In the hypophysis, the pars intermedia is strongly labeled. Within the hippocampal formation, slightly higher binding site densities are found in the dentate gyrus. The distribution pattern of binding sites in the dentate gyrus varies according to the species investigated. The data presented in this study permit the conclusion that (3H)buspirone binds with high affinity to dopamine 2 receptors but do not exclude additional binding to other types of receptors, e.g. 5-HT1 receptors. The interaction of buspirone with dopamine 2 receptors may be mainly responsible for its pharmacological profile.

Animals↗
PubMed1991

Effects of sigma receptor ligands on schedule-controlled behavior of rats: relation to sigma and PCP receptor binding affinity.

Eleven drugs were examined for their ability to inhibit sigma and phencyclidine (PCP) receptor binding, as labelled by (+)[3H]-R-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine ((+)-3-PPP), [3H]ditolylguanidine (DTG), (+)[3H]N-allylnormetazocine (NANM) and [3H]1-(1-(2-thienyl)cyclohexyl)piperidine (TCP), in membrane preparations from whole rat brain. The same drugs were studied for their effects under a fixed-ratio (FR) schedule of food reinforcement in rats. The relative potency order of the drugs for decreasing FR responding was: haloperidol greater than (+)-3-PPP greater than (-)NANM greater than BMY 14802 greater than PCP greater than (+)NANM greater than DTG greater than rimcazole greater than JO 1783 greater than JO1784 greater than (-)butaclamol. The binding affinities of all 11 drugs for either the [3H]DTG, (+)[3H]-3-PPP, (+)[3H]NANM or [3H]TCP site did not correlate significantly with the potencies of the same drugs for decreasing FR behavior. Rimcazole, (+)-3-PPP and haloperidol, at behaviorally inactive doses, were studied for their effects as antagonists of the rate-decreasing effects of JO 1784, DTG and (+)NANM: rimcazole attenuated the effects of DTG and (+)NANM but not JO 1784; (+)-3-PPP attenuated the effects of (+)NANM but not JO 1784 and DTG; and haloperidol was devoid of antagonistic actions. Moreover, BMY 14802 did not attenuate the rate-decreasing effects of (+)-3-PPP. These results further indicate that it is difficult to distinguish between purported sigma agonist and antagonist drugs.

Animals↗
PubMed1991

On the selection of mice for haloperidol response and non-response.

Mice have been selected over eight generations for response and non-response to haloperidol-induced catalepsy. The selection has been asymmetric, with significantly faster divergence for the haloperidol non-responder (HNR) line as compared to the haloperidol responder (HR) line. After six generations of selection, the ED50 in the HNR line was 4.3 mg/kg and 0.4 mg/kg in the HR line. Spiroperidol, fluphenazine and trifluoperazine showed a 10-fold or greater discrimination between lines. Raclopride, a specific dopamine D2 antagonist, showed a 7-fold discrimination between lines. Chlorpromazine, thiothixene, (+) butaclamol and cis-flupenthixol showed a 3-4-fold discrimination between lines. The specific D1 antagonist, SCH 23390, was the most potent cataleptogenic agent tested (ED50 = 0.1 mg/kg) and did not discriminate between the lines. The HR and HNR lines did not differ in post-synaptic D2 receptor affinity or density as assessed by quantitative receptor autoradiography and membrane binding assays. However, A-9 somatodendritic receptor density was 80% higher in the HNR line as compared to the HR line.

Animals↗
PubMed1998

Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists.

The novel benzodioxopiperazine, 5-HT1A receptor weak partial agonist, S 15535 (4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine) bound with high affinity and selectivity to membranes of Chinese Hamster Ovary cells stably expressing the human (h) 5-HT1A receptor (Ki = 0.6 nM versus [3H]-8-hydroxy-dipropylamino-tetralin, [3H]-8-OH-DPAT): its affinity at h5-HT1A receptors was more than 70-fold higher than its affinity at > 50 other binding sites. S 15535 was tritiated to high specific activity (50 Ci/mmol) and its binding profile characterised. At 22 degrees C, [3H]-S 15535 associated and dissociated from h5-HT1A receptors with half-times of 2.9 and 5.0 min, respectively, yielding a Kd estimate of 3.6 nM. In saturation binding experiments, [3H]-S 15535 displayed a Bmax value for h5-HT1A receptors (1630 fmol/mg), higher than that obtained with the agonist [3H]-8-OH-DPAT (1023 pmol/mg). Guanylyl imidodiphosphate (GppNHp, 100 microM) reduced the binding of [3H]-S 15535 by only 25% compared with 79% for [3H]-8-OH-DPAT at h5-HT1A receptors. [3H]-S 15535 also showed high affinity, saturable binding to rat hippocampal membranes (Bmax = 820 fmol/mg versus 647 fmol/mg for [3H]-8-OH-DPAT). For both h5-HT1A and rat 5-HT1A receptors, the Ki values for competition binding of 15 serotonergic ligands with [3H]-S 15535 was highly correlated with that of [3H]-8-OH-DPAT. However, important differences were also observed. The agonist, 5-hydroxytryptamine (5-HT), displayed biphasic competition curves with [3H]-S 15535 but not with [3H]-8-OH-DPAT at h5-HT1A receptors. Similarly, the 'antagonists', spiperone, methiothepin and (+)butaclamol, showed biphasic competition isotherms versus [3H]-S 15535 but not [3H]-8-OH-DPAT. When [3H]-S 15535 competition binding experiments were carried out in the presence of GppNHp (100 microM) the 5-HT and 8-OH-DPAT competition curves shifted to the right, whereas the spiperone and methiothepin competition curves shifted to the left. In contrast, in the presence of GppNHp, the competition isotherms for N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclo-h exanecarboxamide (WAY 100,635) were not altered. Taken together, these data show that (i) [3H]-S 15535 is a highly selective 5-HT1A receptor ligand which labels both G-protein-coupled and uncoupled 5-HT1A receptors, (ii) antagonists, such as WAY 100,635, which yield monophasic isotherms in competition with both [3H]-agonists and [3H]-antagonists, are not sensitive to the G-protein coupling state of the receptor, but (iii) spiperone and methiothepin behaved as inverse agonists, their competition isotherms with [3H]-S 15535 being modulated in an opposite manner to those of agonists.

8-Hydroxy-2-(di-n-propylamino)tetralin↗
PubMed1980

Identification and partial purification of a hydrophobic protein component associated with [3H]spiroperidol-binding activity.

The binding activity of radiolabelled neuroleptic drugs has been used to biochemically and pharmacologically characterize the dopamine receptor in brain. An extract which binds [3H]spiroperidol and exhibits stereoselectivity for (+)- and (-)-butaclamol, has been isolated from the calf striatal microsomal fraction. Specific binding activity in the chloroform-methanol extract of this preparation is enhanced over that of the crude homogenate. The highest specific binding of the chloroform methanol extract is associated with the crude phospholipid component which is enriched in hydrophobic proteins and acidic phospholipids. Subfractionation of the crude phospholipid extract by gel filtration (Sephadex LH-20) yields multiple peaks of [3H]spiroperidol binding activity, however four major zones of specific binding activity were detected. These results demonstrating a close association of phospholipids with a dopamine binding site suggest a functional role for proteolipid in receptor recognition and regulation.

Animals↗
PubMed1987

Dopamine binding to the alpha receptor in pregnant rabbit myometrium.

This study evaluated in vitro binding of dopamine ligands to myometrial alpha adrenoceptors. With cell membranes from pregnant rabbits, receptor radioligand binding studies utilizing [3H] dihydroergocryptine +/- dopamine demonstrated receptor affinity (KD) = 0.75 +/- 0.10 nM (+/- SEM) and density (Bmax) = 533.2 +/- 45.2 fM/mg protein. Similar studies utilizing phentolamine or apomorphine gave essentially identical results. Competition binding studies demonstrated steriospecific butaclamol binding, along with significant binding of haloperidol, spiperone, apomorphine, and bromoergocryptine. These observations provide a mechanism for the observed uterotonic effects of dopamine.

Animals↗
PubMed1982

Dopamine receptors in rat brain regions. Optimal conditions for 3H-agonist binding, pH dependency and lack of inhibition by ascorbic acid.

The binding of dopaminergic agonist and antagonist radioligands was investigated in rat brain regions. A 30-min preincubation of homogenates of caudate nucleus or mesolimbic brain regions at 37 degrees induced a several-fold increase in the stereospecific binding of [3H]-dopamine or [3H]apomorphine to the subsequently washed particulate fraction, whereas it induced a slight decrease in [3H]spiroperidol binding. Stereospecific 3H-agonist binding was not observed in brain regions devoid of dopaminergic innervation. Guanosyl nucleotides, EDTA or ethyleneglycol-bis-(beta-amino-ethyl ether) N,N'-tetraacetate (EGTA), included in the preincubation buffer, antagonized the stimulation of 3H-agonist binding. The stereospecific binding sites of 3H-agonists were saturable with equilibrium dissociation constants (Kd) of 1-2 nM. High-affinity binding was pH dependent, with different pH optima for each radioligand. Several dopamine receptor agonists and antagonists were potent inhibitors of stereospecific [3H]dopamine binding, whereas l-ascorbic acid was inactive at concentrations as high as 1.0 mM. The stereospecific binding of [3H]apomorphine or [3H]spiroperidol was also unaffected by ascorbic acid. The nonspecific (d-butaclamol-insensitive) portion of 3H-agonist binding was weakly inhibited by concentrations of ascorbic acid higher than 0.01 mM. This effect was also observed in the cerebellum and spinal cord, where none of the 3H-agonist binding was stereospecific. It is concluded that the portion of 3H-agonist or 3H-antagonist radioligand binding which is related to dopamine receptors is unaffected by ascorbic acid.

Animals↗
PubMed1986

Solubilization of dopamine D2 receptors with a zwitterionic detergent DCHAPS.

Dopamine D2 receptors were solubilized from synaptosomal membranes of the bovine caudate nucleus using a novel zwitterionic detergent 3-[(3-deoxycholamidopropyl)-dimethylammonio]-1-propane sulfonate (DCHAPS) supplemented with 1,2-propylene glycol. Optimal conditions for solubilization were: 0.12% DCHAPS, 5% 1,2-propylene glycol, 8 mg/ml membrane protein, 30 min, 4 degrees and the yield of the D2 receptors was 36.1%. The soluble extract retained the ability to bind [3H]spiperone. This binding was of high affinity (Kd = 2.28 +/- 0.16 nM), reversible and saturable (Bmax = 1.68 +/- 0.06 pmol/mg protein). The order of potencies of dopamine agonists and antagonists for inhibition of binding, paralleled that observed on membrane-bound D2 receptors (correlation factor r = 0.96). The stereo-specificity of solubilized receptors toward the pairs (+)-[(-)butaclamol, cis(Z)-]trans(E)flupenthixol and dihydroergosine/dihydroergosinine was pronounced.

Animals↗
PubMed1990

Effects of monovalent cations on neostriatal dopamine D2 receptors labeled with [3H]raclopride.

Specific [3H]raclopride binding to dopamine D2 receptors in the rabbit neostriatum was investigated in the presence of the monovalent cations sodium, lithium and potassium. NaCl and LiCl produced concentration-dependent elevations in specific [3H]raclopride binding with sodium inducing approximately 50% more binding than lithium. Inhibition of [3H]raclopride binding by the antagonist (+)-butaclamol was unaffected by the presence of sodium or lithium in the incubation medium. In contrast, the potency of dopamine to compete with [3H]raclopride was decreased by these two ions. This effect was more pronounced in the presence of sodium than lithium and was observed for both the high- and low-affinity states of the D2 receptor. The guanine nucleotide derivative 5'-guanylylimidodiphosphate (Gpp(NH)p) reduced the potency of dopamine to compete with [3H]raclopride binding in both the presence and absence of cations; however, this effect of Gpp(NH)p was a shift of the D2 receptors from a high to a lower affinity state. Saturation binding curves in the presence of sodium or lithium were compared with experiments carried out in the absence of monovalent cations (sucrose) and demonstrated that these ions increased the affinity (judged by the equilibrium dissociation constant Kd) of the neostriatal [3H]raclopride binding sites. While NaCl produced a significantly greater change in the Kd of [3H]raclopride binding as compared to LiCl, no differences were apparent in the maximum binding capacity (Bmax) values determined in the presence of these two cations. In conclusion, the results indicate that [3H]raclopride binding to rabbit neostriatal membranes exhibits a sensitivity to monovalent cations that is consistent with the ionic regulatory properties of the D2 receptor. Moreover, although lithium and sodium influence specific [3H]raclopride binding in a similar manner, there appear to be quantitative differences between these two ions.

Animals↗
PubMed1992

3H-spiroperidol binding to human peripheral mononuclear cells: methodological aspects.

3H-spiroperidol binding to lymphocytes has been proposed as a vulnerability marker for schizophrenia. However, the biological significance and even existence of this "binding site" are still in controversy. Therefore, the present study reevaluated methodological details using a filtration binding assay. The results indicated that some well-known, but obviously uncontrolled pitfalls might contribute to this controversy [e.g., unspecific filter binding, which increased in the presence of (+)-butaclamol, or a variable amount of contaminating granulocytes). Moreover, due to an atypically shaped saturation curve, different mathematical methods to analyze the data were used and compared. The present data should help us to understand the biological relevance of this marker, as viewed in different laboratories.

Adult↗
PubMed1996

D2-like dopamine receptors are not detectable on human peripheral blood lymphocytes.

The binding of [3H]-nemonapride to human peripheral blood lymphocytes (PBL) was studied using various competing ligands specific for D2-like dopamine receptors. There is no detectable stereoselectivity for the stereoisomers of butaclamol, and competitions with haloperidol and sulpiride also show no evidence of specific binding to D2-like dopamine receptors. RT-PCR of RNA from human lymphocytes showed that there is no detectable D2 mRNA (even with nested PCR). D3 mRNA was, however, detectable by RT-PCR, but only at low levels that could not be detected by Northern blots of PBL total RNA.

Adult↗
PubMed1980

Noradrenergic afferents to median eminence: inhibitory role in rhythmic growth hormone secretion.

The involvement of noradrenergic (NA) afferents to the median eminence (ME) in the regulation of growth hormone (GH) secretion was investigated in chronically cannulated, unanaesthetized male rats by using systemically administered 6-hydroxy-dopamine (6-OHDA). One day after 6-OHDA treatment (50 mg/kg, i.v.) GH peak frequency was substantially increased and examination of catecholamine (CA) fluorescence indicated disruption of CA innervation of the ME, but not other central nervous system (CNS) structures. Prolactin secretion at this time was normal and the administration of butaclamol (1.0 mg/kg, i.v.), a dopamine (DA) antagonist, was effective in increasing secretion, indicating that ME DA mechanisms were functionally intact following 6-OHDA treatment. GH secretory patterns returned to normal by 21 days following 6-OHDA treatment and this corresponded with re-emergence of a normal pattern of CA-fluorescence in the ME. In an additional study, the administration of the alpha-NA agonist clonidine (130 microgram/kg, i.v.) increased GH secretion in previously untreated animals. Administration of the alpha-NA agonist oxymetazoline (45 microgram/kg, i.v.), which does not readily pass the blood-brain barrier (BBB), suppressed GH secretion. These findings indicate that ME NA afferents are inhibitory to GH secretion and are a major determinant of the 3 h pattern of GH release in the rat. This inhibitory input is subsidiary to a NA stimulatory input to an as yet unidentified site inside the BBB.

Afferent Pathways↗
PubMed1981

Modulation of slow postsynaptic potentials by dopamine, in rabbit sympathetic ganglion.

(1) Temporary exposure of rabbit's superior cervical ganglion (SCG) to dopamine (DA), in the presence of an inhibitor of catechol-o-methyltransferase (COMT) is consistently followed by a potentiation of the slow (s)-EPSP and s-IPSP, lasting for some hours. The fast (f)-EPSP is not significantly increased, but it is better maintained than in control ganglia. (2) Exposure to the COMT-inhibitor U-0521 alone induces less but substantial potentiations of both s-PSPs. This effect is explained as due to protection of DA released intraganglionically at rest. (3) This evidence suggests that COMT may significantly limit the access of catecholamines to postsynaptic receptors, for at least certain types of neuron-to-neuron synaptic actions. (4) The potentiation of both s-PSPs, whether induced by DA in the presence of U-0521 or by U-0521 alone, is depressed by DA-1 antagonists that have been found to depress DA-stimulation of adenyl cyclase in rabbit SCG; these are spiroperidol, butaclamol and, to a lesser extent, bromocriptine. The specific 'DA-2' antagonists metoclopramide and sulpiride, and the alpha-adrenergic antagonist dihydroergotamine, did not depress potentiation. (5) Potentiation of s-EPSP is viewed as identical in nature to the previously discovered DA-modulatory enhancement of direct muscarinic depolarizing actions (by acetylcholine or its agonists). Potentiation of s-IPSP may be due to a similar DA-modulation of other muscarinic response(s) involved in mediating the s-IPSP. The consistency and comparative ease with which these DA-modulatory effects can be induced, under presently described experimental conditions, should facilitate future study of this mode of synaptic action.

Animals↗
PubMed1982

Effects of GTP and sodium on rat striatal dopamine receptors labeled with lisuride.

[3H]Lisuride binding to rat striatal membranes appeared to be stereospecifically displaced by the dopamine antagonist butaclamol. Sodium increased the number of [3H]lisuride binding sites (Bmax) without changing the dissociation constant (Kd). GTP did not affect [3H]lisuride binding characteristics, either with or without sodium. These results suggest that dopamine receptor sites labeled by lisuride are at least in part sodium-dependent, possibly the D2-receptors not involved in adenylate cyclase stimulation.

Animals↗